On October 23, 2024, Professor Michael Gnant from Medical University of Vienna in Austria was invited by Cancer Center of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) to carry out international MDT consultation and academic exchange activities for refractory cases of breast cancer. Feng Guanglin, Deputy Secretary of the Party Committee of FAH, directors and physicians of Department of Breast Surgery, Cancer Center, Department of Radiation Oncology, Department of Nuclear Medicine, PET/CT Room and other related departments attended the meeting.
Deputy Secretary Feng Guanglin delivered a speech, appreciating Professor Michael Gnant for his hands-on guidance. He also hoped that in-depth exchange activities can bring valuable experience and further cooperation to the diagnosis and treatment of breast cancer in FAH. Subsequently, Deputy Secretary Feng Guanglin presented the honorary certificate for International Remote Consultation Expert for Refractory Cases to Professor Michael Gnant.
At the meeting, physician Wang Fan from Phase I Clinical Trial Research Center illustrated the construction and development of Phase I Clinical Trial Research Center in FAH.
During academic exchange session, Professor Michael Gnant delivered a thematic presentation entitled "The Future of Clinical Research-Clinical Trials for Breast Cancer". He introduced ABCSG series of studies, and elucidated the application and efficacy of bone-modifying drugs in adjuvant treatment for early postmenopausal HR+ breast cancer patients, sharing his viewpoints on how to identify sensitive population of endocrine therapy in the future and designing multiple clinical studies for such sensitive population. He also discussed how to prolong endocrine therapy for postmenopausal women. According to ABCSG-16 clinical research, he illustrated the efficacy and risk of AI-assisted endocrine therapy at different time points. Finally, Professor Michael Gnant predicted the future clinical research and treatment direction of breast cancer. Experts attending the meeting conducted in-depth discussions and academic exchanges with Professor Michael Gnant regarding the hotspot issues by integrating the latest research progress.
In the session of MDT case consultation, physician Yang Jiao from Department of Oncology reported a young female patient with refractory triple-negative breast cancer (TNBC). Professor Michael Gnant and MDT experts from FAH conducted in-depth exchanges and discussions on optimal neoadjuvant treatment strategy for TNBC, the selection of adjuvant treatment for postoperative PCR patients, and treatment regimen for young high-risk TNBC. Professor Michael Gnant proposed targeted suggestions on the selection of subsequent treatment plan based on clinical diagnosis and treatment characteristics of this patient. Multiple experts delivered intense exchanges with Professor Michael Gnant regarding the diagnosis and treatment of TNBC.
